Scopus Biopharma Inc (SCPS) Finansal

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is developing therapeutics targeting serious diseases with significant unmet medical needs. Its lead development programs are CO-sTiRNA and MRI-1867. Its CO-sTiRNA is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. CO-sTiRNA is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA also stimulates TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells. The company is also developing MRI-1867 for the treatment of SSc. SSc is a chronic, systemic autoimmune disease. MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.